Anecortave acetate as monotherapy for treatment of subfoveal neovascularization in age-related macular degeneration: twelve-month clinical outcomes.

@article{Damico2003AnecortaveAA,
  title={Anecortave acetate as monotherapy for treatment of subfoveal neovascularization in age-related macular degeneration: twelve-month clinical outcomes.},
  author={Donald J. D'amico and Morton Goldberg and Henry L. Hudson and Janice A Jerdan and D Scott Krueger and Susan P Luna and Stella M. Robertson and Stephen Russell and Lawrence J. Singerman and Jason S. Slakter and Lawrence A. Yannuzzi and Patricia Zilliox},
  journal={Ophthalmology},
  year={2003},
  volume={110 12},
  pages={2372-83; discussin 2384-5}
}
PURPOSE To evaluate safety and efficacy of the angiostatic agent anecortave acetate, compared with a placebo, for treatment of subfoveal choroidal neovascularization (CNV). DESIGN Ongoing masked, randomized, placebo-controlled, parallel evaluation of anecortave acetate (30 mg, 15 mg, and 3 mg) versus a placebo. PARTICIPANTS There were 128 eyes of 128 patients with subfoveal CNV secondary to age-related macular degeneration who were enrolled and treated, with 80% (102/128) of eyes presenting… CONTINUE READING
41 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 41 extracted citations

Similar Papers

Loading similar papers…